Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
A small phase II trial reported limited efficacy of T-DM1 monotherapy in 15 relapsed HER2 -altered NSCLC patients with an objective response rate (ORR) of 6.7% and median progression-free survival (PFS) and overall survival (OS) of 2 (95% confidence interval [CI], 1.4 to 4) and 10.9 months (95% CI, 4.4 to 12), respectively
Reports of temporary tiredness or mild headaches when first starting have been reported
Weve been helping individuals reach their goals since 2013, and were ready to help you, too
Supplementation increases phosphocreatine stores in skeletal muscle, which serves as a rapid energy reserve during high-intensity, short-duration activities
US$ 27.81
US$ 20.53
US$ 29.61
US$ 25.66
